Abstract
Oxidative/nitrosative stress and mitochondrial dysfunction is a hallmark of amyotrophic lateral sclerosis (ALS), an invariably fatal progressive neurodegenerative disease. Here, as an exploratory arm of a phase II clinical trial (EudraCT Number 2017-005065-47), we used high performance liquid chromatography(HPLC) to investigate changes in the metabolic profiles of serum from ALS patients treated weekly for 4 weeks with a repeated sub-cutaneous dose of 1 mg/kg of a proprietary low molecular weight dextran sulphate, called ILB®. A significant normalization of the serum levels of several key metabolites was observed over the treatment period, including N-acetylaspartate (NAA), oxypurines, biomarkers of oxidative/nitrosative stress and antioxidants. An improved serum metabolic profile was accompanied by significant amelioration of the patients’ clinical conditions, indicating a response to ILB® treatment that appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (neuro)inflammatory processes.
Original language | English |
---|---|
Article number | 794 |
Number of pages | 15 |
Journal | Journal of Personalized Medicine |
Volume | 11 |
Issue number | 8 |
DOIs | |
Publication status | Published - 14 Aug 2021 |
Bibliographical note
Funding Information:This research was funded by Tikomed AB, who had no influence on the conduct of the trial and was not involved in data collection or analysis.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
- Amino acids
- Amyotrophic lateral sclerosis
- Antioxidants
- Energy metabolism
- HPLC
- Low molecular weight-dextran sulphate
- Mitochondrial dysfunction
- N-acetylaspartate
- Oxidative/nitrosative stress
- Serum biomarkers
ASJC Scopus subject areas
- Medicine (miscellaneous)